Table 5.
The combined action between the tested antibiotics and the prepared nanoformulae.
| Treatment/M.OS | Inhibition Zone Diameter (mm) | ||||
|---|---|---|---|---|---|
| Staphylococcus aureus | Klebsiella pneumoniae | Escherichia coli | Pseudomonas aeruginosa | Acinetobacter baumannii | |
| Sericin | 8.0 | 8.0 | 7.5 | 7.0 | 7.5 |
| Propolis | 7.5 | 8.0 | 7.0 | 7.0 | 7.0 |
| nSE/P | 22.0 | 9.0 | 9.0 | 8.0 | 12.0 |
| Cephalexin | 11.7 | 12.5 | 10.5 | 9.5 | 10.0 |
| nSE/P/Cephalexin | 45.0 | 30.0 | 25.5 | 24.5 | 25.3 |
| Colistin | 10.0 | 11.0 | 9.0 | 8.6 | 9.0 |
| nSE/P/Colistin | 22.0 | 27.5 | 19.0 | 18.0 | 19.0 |
| Amoxicillin | 11.0 | 12.0 | 9.7 | 9.0 | 9.5 |
| nSE/P/Amoxicillin | 34.0 | 26.4 | 22.0 | 20.0 | 21.0 |
| Tetracycline | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 |
| nSE/P/Tetracycline | 15.0 | 8.0 | 6.0.0 | 6.0 | 6.0 |
| Tegycicline | 22.0 | 17.0 | 25.0 | 17.0 | 14.0 |
| nSE/P/Tegycicline | 15.0 | 6.0 | 6.0 | 6.0 | 12.0 |
| Chloramphenicol | 25.0 | 20.0 | 6.0 | 6.0 | 7.0 |
| nSE/P/Chloramphenicol | 25.0 | 20.0 | 6.0 | 6.0 | 7.0 |
| Ampicillin-sulbactam | 16.0 | 6.0 | 13.0 | 6.0 | 10.0 |
| nSE/P/Ampicillin-sulbactam | 19.0 | 6.0 | 13.0 | 6.0 | 12.0 |
| Cefotaxime | 12.0 | 13.0 | 15.0 | 15.0 | 14.0 |
| nSE/P/Cefotaxime | 14.0 | 11.0 | 14.0 | 10.0 | 12.0 |
| Cefuroxime | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 |
| nSE/P/Cefuroxime | 17.0 | 6.0 | 6.0 | 6.0 | 6.0 |
| Gentamicin | 23.0 | 22.0 | 10.0 | 10.0 | 8.0 |
| nSE/P/Gentamicin | 23.0 | 24.0 | 10.0 | 12.0 | 8.0 |
| Cefoperazone | 22.0 | 25.0 | 20.0 | 19.0 | 14.0 |
| nSE/P/Cefoperazone | 25.0 | 25.0 | 23.0 | 22.0 | 16.0 |
| Azithromycin | 6.0 | 15.0 | 13.0 | 6.0 | 12.0 |
| nSE/P/Azithromycin | 15.0 | 14.0 | 10.0 | 6.0 | 10.0 |
| Ceftazidim | 6.0 | 13.0 | 13.0 | 6.0 | 10.0 |
| nSE/P/Ceftazidim | 15.0 | 6.0 | 6.0 | 6.0 | 10.0 |
| Amikacin | 25.0 | 23.0 | 24.0 | 25.0 | 7.0 |
| nSE/P/Amikacin | 30.0 | 24.0 | 24.0 | 28.0 | 9.0 |